These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 25862597

  • 1. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q, Ming WK, Yip WY, You JHS.
    Int J Infect Dis; 2019 Jan 08; 78():44-49. PubMed ID: 30342251
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015 Jan 08; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 01; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ, Gibbert J, Wirth D, Diel R.
    Eur Respir J; 2015 Dec 01; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S, Yigezu A, Hailemariam D, Hailu A.
    PLoS One; 2020 Dec 01; 15(7):e0235820. PubMed ID: 32716915
    [Abstract] [Full Text] [Related]

  • 14. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE, Hill A.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1243-1252. PubMed ID: 28073970
    [Abstract] [Full Text] [Related]

  • 15. Cost of multidrug resistant tuberculosis in Germany-An update.
    Diel R, Sotgiu G, Andres S, Hillemann D, Maurer FP.
    Int J Infect Dis; 2021 Feb 01; 103():102-109. PubMed ID: 33157286
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
    Byun JH, Park JA, Kang HR, Shin JY, Lee EK.
    Clin Drug Investig; 2016 Nov 01; 36(11):957-968. PubMed ID: 27465204
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of interventions for tuberculosis control: DALYs versus QALYs.
    Diel R, Lampenius N.
    Pharmacoeconomics; 2014 Jul 01; 32(7):617-26. PubMed ID: 24849396
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.